slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 217,111-217,140
Pages 10,126
Rows per page 30
Component
217,111-217,140 of 303,780
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citrate-free formulation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
29
The slide uses qualitative expert feedback to support quantitative preference share data.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
30
The slide uses a table-like layout to represent a drug development pipeline.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
35
The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
36
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
37
The visual uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
38
The slide uses a matrix-like layout to map targets and programs against development stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
42
The slide uses a timeline-based process diagram to illustrate the clinical trial strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
43
The slide uses a Y-shaped antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
45
The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
51
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
52
The slide serves as a credibility transfer by showcasing the partner's team and achievements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
53
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit